Novartis just handed out a $8.7 billion endorsement for new therapies that are changing how we treat genetic diseases

This post was originally published on this site

Novartis is acquiring gene therapy company AveXis for $US8.7 billion. AveXis is working on a gene therapy for spinal muscular atrophy, a rare genetic condition that affects muscle movement in children and is the leading genetic cause of mortality in infants.
More »